IDEAYA Biosciences

Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.

IDEAYA Biosciences has submitted an IND application to the FDA for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor targeting MTAP-deleted solid tumors.

Servier and IDEAYA Biosciences announced an exclusive licensing agreement worth up to $530 million for darovasertib, a protein kinase C inhibitor targeting uveal melanoma, a rare and aggressive eye cancer.

IDEAYA Biosciences will present Phase 2 clinical data on neoadjuvant darovasertib in primary uveal melanoma at the 2025 ESMO meeting in Berlin.

IDEAYA Biosciences has received FDA clearance for a Phase 1 clinical trial of IDE849, a potential first-in-class DLL3-targeting Topo-I-payload antibody drug conjugate for solid tumors including small cell lung cancer and neuroendocrine tumors.

The FDA has granted Breakthrough Therapy designation to darovasertib, a first-in-class protein kinase C inhibitor, for neoadjuvant treatment of primary uveal melanoma patients facing eye removal.

IDEAYA Biosciences and GSK will present promising data on IDE275 (GSK959), a potential best-in-class Werner Helicase inhibitor for MSI-H solid tumors, at AACR 2025's New Drugs on the Horizon series.

• IDEAYA Biosciences has formed a strategic collaboration with ATTMOS to develop a physics-based computational platform for discovering small molecule drugs targeting previously undruggable oncology targets. • The partnership will focus on implementing high-throughput absolute binding free energy perturbation predictions (ABFEP) to enable more accurate and efficient virtual screening of drug candidates. • The collaboration leverages IDEAYA's expertise in structural biology and drug discovery combined with ATTMOS's computational chemistry capabilities to overcome current limitations in AI/ML approaches for novel drug targets.

• Amgen and Ideaya Biosciences have mutually agreed to discontinue their clinical collaboration testing the combination of AMG 193 and IDE397 for solid tumors. • Ideaya will pivot to studying IDE397 in combination with its own PRMT5 inhibitor IDE892 for non-small cell lung cancer treatment. • Amgen continues development of AMG 193 monotherapy, which showed 21.4% objective response rate across multiple tumor types, and has initiated Phase II trials in NSCLC.

IDEAYA Biosciences advances multiple oncology programs, with over 230 patients enrolled in potential registration-enabling trial for darovasertib in metastatic uveal melanoma, targeting key readouts by end of 2025.